BBLG BONE BIOLOGICS CORP revenue, earnings and financials
For the quarter ended September 30, 2026, BONE BIOLOGICS CORP reported revenue of n/a, net income of −$618K and diluted EPS of −$0.17; for the fiscal year ended December 2025 revenue was n/a.
BBLG annual revenue and earnings
- Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income −$3.23M, net income −$3.11M (margin n/a), EPS −$2.65
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$4.22M, net income −$4.11M (margin n/a), EPS −$28.96
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income −$9.43M, net income −$8.95M (margin n/a), EPS −$34.01
- Fiscal year ended Dec 2022: revenue n/a, gross profit n/a, operating income −$3.67M, net income −$1.48M (margin n/a), EPS −$31.15
- Fiscal year ended Dec 2021: revenue n/a, gross profit n/a, operating income −$1.10M, net income −$1.61M (margin n/a), EPS −$0.35
BBLG quarterly revenue and earnings
- Quarter ended Sep 30, 2026: revenue n/a, net income −$618K, EPS −$0.17
- Quarter ended Jun 30, 2026: revenue n/a, net income −$774K, EPS −$0.43
- Quarter ended Mar 31, 2026: revenue n/a, net income −$766K, EPS −$0.43
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$685K, EPS $0.97
- Quarter ended Sep 30, 2025: revenue n/a, net income −$667K, EPS −$0.37
- Quarter ended Jun 30, 2025: revenue n/a, net income −$741K, EPS −$1.33
- Quarter ended Mar 31, 2025: revenue n/a, net income −$1.02M, EPS −$1.92
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$1.52M, EPS −$9.42
- Quarter ended Sep 30, 2024: revenue n/a, net income −$941K, EPS −$14.21
- Quarter ended Jun 30, 2024: revenue n/a, net income −$784K, EPS −$4.02
- Quarter ended Mar 31, 2024: revenue n/a, net income −$866K, EPS −$1.31
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$1.55M, EPS $31.30
- Quarter ended Sep 30, 2023: revenue n/a, net income −$1.92M, EPS −$4.90
- Quarter ended Jun 30, 2023: revenue n/a, net income −$1.77M, EPS −$5.21
- Quarter ended Mar 31, 2023: revenue n/a, net income −$3.71M, EPS −$55.20
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income $893K, EPS n/a
- Quarter ended Sep 30, 2022: revenue n/a, net income −$1.22M, EPS −$3.53
- Quarter ended Jun 30, 2022: revenue n/a, net income −$469K, EPS −$1.36
- Quarter ended Mar 31, 2022: revenue n/a, net income −$689K, EPS n/a
- Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$178K, EPS −$0.05
BBLG cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$2.69M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$4.12M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$9.56M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$3.57M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$1.23M, share buybacks n/a
BBLG balance sheet
- Sep 30, 2026: cash n/a, total assets $6.43M, total liabilities $481K, shareholders' equity $5.95M
- Jun 30, 2026: cash n/a, total assets $4.44M, total liabilities $512K, shareholders' equity $3.92M
- Mar 31, 2026: cash n/a, total assets $4.98M, total liabilities $309K, shareholders' equity $4.67M
- Dec 31, 2025: cash n/a, total assets $5.80M, total liabilities $419K, shareholders' equity $5.38M
- Sep 30, 2025: cash n/a, total assets $6.35M, total liabilities $334K, shareholders' equity $6.02M
- Jun 30, 2025: cash n/a, total assets $7.00M, total liabilities $406K, shareholders' equity $6.60M
- Mar 31, 2025: cash n/a, total assets $3.16M, total liabilities $251K, shareholders' equity $2.91M
- Dec 31, 2024: cash n/a, total assets $3.86M, total liabilities $378K, shareholders' equity $3.48M
Is BBLG profitable?
No. BONE BIOLOGICS CORP lost $2.84M over the last four quarters.
What is BBLG's EPS?
Diluted earnings per share over the last four quarters were −$0.06; −$0.17 in the latest quarter.